2型糖尿病与痴呆发展息息相关

2016-11-22 赛诺菲医学部 菲糖新动

导语:痴呆给2型糖尿病(T2DM)患者带来了沉重的负担。2016年9-10月期间,Diabetologia、PLoS One以及Diabetes Care杂志相继发表了三项研究,分别从T2DM患者的痴呆风险、低血糖与痴呆关系以及载脂蛋白E(APOE)与认知关系三方面进行探讨,为我们带来了糖尿病与痴呆的最新进展。T2DM患者的痴呆发作、发生率及风险Fremantle糖尿病研究I期(FDS1)是一

导语:痴呆给2型糖尿病(T2DM)患者带来了沉重的负担。2016年9-10月期间,Diabetologia、PLoS One以及Diabetes Care杂志相继发表了三项研究,分别从T2DM患者的痴呆风险、低血糖与痴呆关系以及载脂蛋白E(APOE)与认知关系三方面进行探讨,为我们带来了糖尿病与痴呆的最新进展。


T2DM患者的痴呆发作、发生率及风险

Fremantle糖尿病研究I期(FDS1)是一项在澳大利亚进行的以社区为基础的纵向队列研究,本研究纳入FDS1中1,291例T2DM患者,并通过澳大利亚西部数据联动系统(WADLS)选择了5,159例非糖尿病者作为对照组,旨在对T2DM患者和非T2DM人群的痴呆发生年龄、死亡年龄、生存时间及痴呆发生率进行比较。随访时间13.8±5.8年。

T2DM与痴呆发生率增加有关

随访期间,T2DM患者与非糖尿病者痴呆发生率分别为13.9%和12.4%(P=0.15)。T2DM与全因痴呆发生率显著增加相关(总体发生率比值[IRR]:1.28),尤其是在更年轻的人群中相关性更显著,55-64岁、65-74岁、75-84岁和≥85岁患者的IRR分别为4.19、1.64、1.43和1.43。

与非糖尿病患者相比,T2DM患者痴呆发作更早、死亡时间更早

T2DM患者痴呆发作时间较非糖尿病患者早1.7年(95%CI:0.6-2.9,P=0.004)。此外,痴呆死亡患者中,T2DM患者的死亡时间较非糖尿病患者平均早2.3年(95%CI:1.1-3.6,P<0.001),中位存活时间比非糖尿病患者少0.6年,但差异未达统计学意义(P=0.08)。

T2DM与全因痴呆相关

Cox比例风险模型与Fine-Gary模型分析显示,校正基线年龄、性别和合并症后,T2DM与全因痴呆相关(亚分布风险比[sdHR]:1.18,95%CI:1.00-1.39;特定原因风险比[csHR]:1.51,95%CI:1.27-1.78)。

综上,T2DM与痴呆发生率和相对风险增加相关。与非糖尿病社区居民相比,T2DM患者发生痴呆的年龄更早,但存活时间相似。

老年T2DM患者低血糖与痴呆相关

在T2DM患者中,低血糖可能与包括痴呆在内的认知功能障碍有关。韩国国家糖尿病计划(KNDP)研究是一项评估T2DM慢性并发症的最大的、多中心前瞻性观察队列研究,本研究纳入KNDP研究队列中1,957例年龄≥60岁,且无低血糖史或认知功能障碍史的T2DM,旨在探讨低血糖与痴呆及其他认知障碍的相关性。平均随访3.4±0.9年。

与未发生低血糖的患者相比,发生低血糖的患者痴呆发生率更高

随访期间,118例(6.4%)患者发生低血糖事件,痴呆和其他器质性精神障碍发生率分别为7.5次/1000人·年和0.61次/1000人·年。

与未发生低血糖患者相比,发生低血糖的患者痴呆发生率更高,分别为6.83、18.26次/人·年(P=0.0139),但两组人群其他认知功能障碍发生率无显著差异,分别为0.49、2.61次/人·年(P=0.1106)。

低血糖与痴呆风险增加相关

时间依赖的Cox比例风险模型显示,低血糖与痴呆风险增加相关(校正后风险比[HR]*:2.689,95%CI:1.080-6.694,P=0.0335)。
*校正年龄、性别、吸烟和饮酒状态、基线体重指数(BMI)、舒张压、糖尿病病程、用药史、基线药物、总胆固醇和低密度脂蛋白-胆固醇(LDL-c)、随访期间的平均HbA1c和用药。

低血糖发生次数与痴呆风险呈线性相关

与发生一次低血糖事件的患者相比,发生两次或以上低血糖事件的患者发生痴呆的风险增加(HR:4.065,95%CI:1.099–15.039,P=0.0356)。低血糖事件发生次数增加与痴呆风险增加呈线性相关(P=0.0286)。

综上,在韩国老年T2DM患者中,低血糖与痴呆风险增加相关,且与低血糖事件次数呈正相关。在老年T2DM患者的管理中,为了预防认知障碍和生活质量恶化,应该重视低血糖的预防。

APOE基因型与认知能力相关,而非脑结构

之前的研究表明,与痴呆晚期发作最为相关的遗传因素是APOE。本研究对糖尿病心脏研究(DHS-MIND)中754例欧洲裔美国人,以及非洲裔美国人糖尿病心脏研究(AA-DHS MIND)中517例非洲裔美国人进行分析,根据AOPE蛋白亚型(APOE2、APOE3、APOE4)对基因单体型进行定义,评估T2DM患者AOPE基因型与认知能力以及脑结构的相关性。

APOE E2和E4单体型组与3MSE和RAVLT表现不佳相关

欧洲裔美国人中,与APOE E3单体型组相比,APOE E4风险单体型组与改良简易精神状态测试(Modified Mini Mental State Examination,3MSE,β=-0.16,P=0.017)和雷伊听觉言语学习测试(Learning and memmory were assessed with the Rey Auditory Verbal Learning Test,RAVLT,β=-0.055,P=0.0089)表现不佳相关,APOE2单体型组与RAVLT(β=-0.046,P=0.032)和音位流畅性(β=-0.082,P=0.047)表现不佳相关。非洲裔美国人中, APOE E4风险单体型组与3MSE(β=-0.14,P=0.014)和RAVLT(β=-0.059,P=0.027)表现不佳相关。

不同种族APOE单体型与认知表现的关系

改良简易精神状态测试(3MSE)评估整体认知;斯特鲁普测试(Stroop task)检测反应抑制作用;数字符号编码任务(Digit Symbol Coding Task)评估执行功能;雷伊听觉言语学习测试(RAVLT)评估学习与记忆;音位流畅性(Phonemic fluency)这里报告为生成字母F的字数。

APOE单体型组与脑结构相关性不强

欧洲裔美国人中,与APOE E3单体型组相比,APOE E4单体型与脑白质病变体积(WMLV)增加相关(β=2.11,P=0.045)。但在非洲裔美国人中,未观察到相关性。

综上,与APOE基因相关的认知能力变化独立于大脑结构的变化。APOE E2和E4与记忆认知结构域和整体认知方面表现不佳相一致。遗传因素的鉴定仍是了解预防和治疗痴呆新途径的关键。

原始出处:

1.Davis WA, Zilkens RR, Starkstein SE, et al. Diabetologia2016 Oct 7
2.Palmer Allred ND, Raffield LM, Hardy JC, et al. Diabetes Care 2016 Oct 4
3.Rhee SY, Hong SM, Chon S, et al. PLoS One 2016 Feb 18

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-23 1e14b1f1m91(暂无匿称)

    写的不错,值得学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-23 半夏微凉

    有了更深的了解。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-23 忠诚向上

    继续努力

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 1e18ec0bm74(暂无匿称)

    对糖尿病有了更深的认识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 1e1263e3m20(暂无匿称)

    很好,学习了,多谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 Anima

    T2MD与痴呆发展息息相关

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 1e13aaccm00(暂无匿称)

    好过分高

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 曲玲

    有帮助,跟我课题相关

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=157741, encodeId=8ddf15e74174, content=写的不错,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98811966002, createdName=1e14b1f1m91(暂无匿称), createdTime=Wed Nov 23 23:55:16 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157566, encodeId=67ea15e5660b, content=有了更深的了解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Wed Nov 23 06:39:36 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157564, encodeId=15c615e564d1, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Nov 23 06:25:15 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157517, encodeId=938515e517a6, content=对糖尿病有了更深的认识, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=892c1984611, createdName=1e18ec0bm74(暂无匿称), createdTime=Tue Nov 22 21:32:01 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157503, encodeId=8f8415e503af, content=很好,学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84e21956153, createdName=1e1263e3m20(暂无匿称), createdTime=Tue Nov 22 21:09:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157499, encodeId=3b9515e49910, content=T2MD与痴呆发展息息相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160807/IMG57A72B38A8C787546.jpg, createdBy=52b31714117, createdName=Anima, createdTime=Tue Nov 22 20:53:55 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157494, encodeId=cf9315e4946e, content=好过分高, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ba1962137, createdName=1e13aaccm00(暂无匿称), createdTime=Tue Nov 22 20:43:49 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157480, encodeId=892415e48091, content=有帮助,跟我课题相关, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJ8mJzaPPxyscLxacenlrV6lE6oiccrLkCfQjcJF6HVnxExcib2g2ca4GhV5iadl9mYWyEJPpibzc7AgA/132, createdBy=f6521954595, createdName=曲玲, createdTime=Tue Nov 22 20:29:16 CST 2016, time=2016-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=157477, encodeId=35ce15e47719, content=确定有关系??, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Tue Nov 22 18:34:02 CST 2016, time=2016-11-22, status=1, ipAttribution=)]
    2016-11-22 乐奕11

    确定有关系??

    0

相关资讯

纪立农教授再谈糖尿病肾病的预测因素

导语:2016年9月,北京大学人民医院内分泌科纪立农教授团队在Diabetes Technology & Therapeutics杂志发表了一项回顾性队列研究。通过收集分析住院2型糖尿病(T2DM)患者数据,探讨T2DM患者(包括正常白蛋白尿者)肾功能下降的主要危险因素。临床上普遍认为白蛋白尿是糖尿病肾病的重要标志物之一,但近年来,越来越多的证据表明,对于某些T2DM患者而言,肾功能改变与

2016AHA科学声明:慢性心衰合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理以及分摊风险发布

2016年10月,美国心脏协会(AHA)发布了关于慢性心衰合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理以及分摊风险的科学声明。高血压,糖尿病,肥胖,高脂血症和代谢综合征是心衰患者常见的合并症并且影响临床结局。本文的主要目的是总结了分摊风险的相关数据并对心衰患者合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理提供指导。全文获取:下载地址:指南下载 (需要扣积分2分, 

CDS 2016:肖新华教授谈糖尿病与甲状腺疾病

肖教授作为中国研究型医院学会糖尿病学专业委员会主任委员,中华医学会糖尿病学分会常 委兼糖尿病营养学组组长,曾以第一或通讯作者发表论文及综述200余篇,主要研究方向是糖尿病的发病机制及早期预防,特殊糖尿病的分子遗传学研究。

CDS 2016:纪立农教授荣获2016年度科学贡献奖,附获奖演讲

由中华医学会、中华医学会糖尿病学分会主办,厦门市医学会承办的中华医学会糖尿病学分会第二十次全国学术会议于2016年11月17在美丽的鹭岛厦门盛大召开。18日下午,CDS的科学贡献奖颁奖仪式及获奖报告在C3展厅隆重举行,本次的获奖者为北京大学人民医院的纪立农教授。科学贡献奖是 CDS 的最高学术奖项,旨在对国内从事糖尿病研究的杰出科研工作者进行表彰,从而鼓励和引导更多同道投身糖尿病科研,促进我国糖尿

CDS 2016:2015年度中国糖尿病十大研究

11月19日中午,中华医学会糖尿病学分会第二十次学术会议(CDS2016)闭幕式在厦门国际会展中心隆重举行。自2013年起,由中华医学会糖尿病学分会设立、《中华糖尿病杂志》承办了“中国糖尿病十大研究”奖项评选。该奖项旨在表彰年度国内糖尿病研究领域做出杰出贡献的专家学者。本次经过独立专家评审小组历时2个月,筛选出30项科学性、创新性俱佳的研究,再经CDS常委会的商议,最终评选出了2015年度的糖

CDS 2016:精彩研究壁报一览

11月17日,厦门市医学会承办的中华医学会糖尿病学分会第二十次全国学术会议盛大开幕了。本次大会作为国内最高水平学术研究的融合,为国内外糖尿病学术提供了交流学习的平台,也为大家献上了最新进展的学术盛宴。梅斯医学小编从会场采集的本届糖尿病学会议壁报一览:1.幽门螺杆菌感染对2型糖尿病患者胃轻瘫的影响及治疗对策2.急性冠脉综合症患者GRACE危险评分于血糖波动关系研究3.沙格列汀作为2型糖尿病患者胰岛素